Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by forhandlarenon Dec 19, 2024 4:14pm
128 Views
Post# 36371027

Make it or break it?

Make it or break it?I've been puzzled by the X publications recently, why bother about South Korea when efforts should be directed to North America for the planned launch?

Also, still no word about the launch partner.

My interpretation is that they try to attract contracts in order to limit the need of launch partner capital and that's a good strategy. It will also take some time until they will get a decent sales cash flow so any contract is welcome.

As long I'm invested I believe in a success, think it's still reachable even though the window probably close in 2025. If successful, I think this company could be THE turn-around of the year.

Before some of the idiots on this board made biorun to leave he shared with me that Abbvie probably would launch their product in Jan 2025. I thought it should be one year earlier but found myself corrected. Let's see if the same applies to him or if we will enjoy a pleasent surprise.
<< Previous
Bullboard Posts
Next >>